Soliris Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Soliris (Eculizumab) is a monoclonal antibody developed by Alexion Pharmaceuticals that inhibits the complement protein C5, helping to reduce inflammation and tissue damage caused by an overactive immune system. It is primarily indicated for rare diseases, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG).

The main forms of Soliris include plasma exchange and plasma infusion. Plasma exchange is a procedure that removes and replaces a patient's plasma to treat conditions such as autoimmune and blood disorders. Soliris is used for applications in PNH and aHUS and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have influenced the soliris market by increasing costs associated with monoclonal antibody production inputs, infusion delivery systems, and cold chain logistics. These impacts are particularly evident in regions reliant on imported orphan biologics such as asia pacific and parts of europe. Hospital procurement costs have risen, affecting reimbursement negotiations. However, tariffs have encouraged localized biologics manufacturing investments. This supports long term access and supply continuity for rare disease treatments.

The soliris market research report is one of a series of new reports from The Business Research Company that provides soliris market statistics, including soliris industry global market size, regional shares, competitors with a soliris market share, detailed soliris market segments, market trends and opportunities, and any further data you may need to thrive in the soliris industry. This soliris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The soliris market size has grown strongly in recent years. It will grow from $2030.44 million in 2025 to $2191.9 million in 2026 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to unmet needs in rare diseases, clinical success in pnh and ahus, regulatory orphan drug incentives, improved patient survival outcomes, limited therapeutic alternatives.

The soliris market size is expected to see strong growth in the next few years. It will grow to $2941.58 million in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to expansion into additional complement mediated diseases, rising rare disease awareness, growth in genetic diagnostics, increased healthcare funding for orphan drugs, long term therapy adherence programs. Major trends in the forecast period include rising adoption of complement inhibitor therapies, growing focus on ultra rare diseases, expansion of long term biologic treatment use, increased genetic testing for rare disorders, high value orphan drug market growth.

The rising prevalence of rare blood disorders is expected to drive the growth of the Soliris market in the coming years. Rare blood disorders are uncommon conditions that affect the blood's production, components, or clotting, including hemophilia, sickle cell anemia, and thalassemia. The increasing prevalence of these disorders is attributed to better diagnostic methods, heightened awareness, and genetic and environmental factors. Soliris works by inhibiting the complement protein C5, helping patients with rare blood disorders by preventing excessive complement activation, which reduces the risk of severe complications such as hemolysis and organ damage, thereby improving overall disease management and patient outcomes. For example, in May 2024, the National Health Service (NHS) England reported that approximately 17,000 people in England are living with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed each year. As a result, the growing prevalence of rare blood disorders is driving the Soliris market.

The increasing investment in rare disease research is also expected to boost the growth of the Soliris market. The surge in funding for rare disease research is driven by the growing recognition of unmet medical needs, advances in genomics, and the potential for breakthrough therapies that improve patient outcomes. Such investment supports Soliris by expanding knowledge of underserved conditions, leading to greater demand for effective treatments. For example, in July 2023, the UK Department of Health and Social Care provided significant funding, including USD 834.2 million (£790 million) for Biomedical Research Centers, USD 15.06 million (£12 million) for the UK Rare Disease Research Platform, and USD 50.2 million (£40 million) for the NIHR BioResource, which connects genetic data to clinical traits across 50 rare diseases to enhance diagnostics and treatment development. Consequently, the growing investment in rare disease research is driving the Soliris market.

A key trend in the Soliris market is the focus on developing biologic therapies for neuromyelitis optica spectrum disorder (NMOSD) to improve treatment options for rare blood disorders. This represents a notable advancement in managing NMOSD, a rare and debilitating autoimmune disease of the central nervous system, by offering an effective therapy that reduces relapses and prevents further neurological damage. For instance, in October 2023, AstraZeneca PLC, a UK-based pharmaceutical company, obtained approval for Soliris (eculizumab) from China's National Medical Products Administration (NMPA) to treat adult patients with NMOSD who are positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This approval made Soliris the first and only complement inhibitor authorized for NMOSD treatment in China.

Major companies operating in the soliris market are Pfizer

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the soliris market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The soliris market consists of sales of soliris (eculizumab) 300 mg/30 mL vial, soliris (eculizumab) injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Soliris Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses soliris market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for soliris ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The soliris market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Plasma Exchange; Plasma Infusion
• 2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH); Atypical Hemolytic Uremic Syndrome (AHUS)
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Pfizer
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.